Summary
Introduction
Overall approximately 3 million women in the US are living with breast cancer. But, even with an increasing incidence, the mortality rate has dropped slightly during the last 10-15 years. The most dramatic decrease is seen in younger patients (<50 years). In the past decade the regulatory authorities in US have approved five hormone-based therapies (Faslodex, Femara, Aromasin, Nolvadex and Arimidex), two chemotherapies (Xeloda and Taxotere) and one monoclonal antibody (Herceptin) as a treatment option for breast cancer. AstraZeneca reported increased sales of Arimidex during 2005 up 38% to $1.2 billion. Faslodex increased (+39%) to $140 million whereas Nolvadex decreased (-16%) to $114 million. Novartis reported that Femara increased it sell value by +30% to $326 million for the first 6 months in 2006. Net U.S. sales of Herceptin increased 56% to $747.2 million in 2005 and 18% to $479.0 million during 2004. According to UK estimates, the switching of 100 000 women from tamoxifen to Arimidex will cost nearly 100 million.
Research and analysis highlights
In the report "Breast Cancer - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of breast cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies. Hormone modifying therapies together with different chemotherapeutic schedules have been of highest intrest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been iniated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
Scope of this report
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
- Key reasons to read this report
Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast cancer R&D, and the results of clinical trials to date
Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy
One hundred high quality references
Some of the drugs included in this analysis:
4HPR, Anastrozole, Arzoxifene, Bevacizumab, Bortezomib, BMS-247550, Erlotinib, Exemestane, Fulvestrant, Gefitinib, Goserelin, Imatinib, KOS-862, Lapatinib, Letrozole, Lonafarnib, NX473, Patupilone, Pemetrexed, Temsirolimus, Theratope, Tipifarnib, Trastuzumab, SDX-105.
Some of the companies included in this analysis:
AstraZeneca, Baxter International, Biomira, Bristol Myers-Squibb, Eli Lilly, Genentech,
GlaxoSmithKline, GTx, Isis Pharmaceuticals, Johnson and Johnson, Lorus Therapeutics, Merck, Millennium Pharmaceutical, NeoRx, Novartis Pharmaceuticals, Pfizer, Roche, Salmedix, Schering-Plough, Wyeth, YM BioSciences
|
